Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current Assets
Cash and cash equivalents (Note 6)	$ 2,622.9	$ 3,818.5
Short-term investments (Note 6)	113.8	90.1
Accounts receivable, net of allowances of $19.2 (2022) and $22.5 (2021)	6,364.5	6,672.8
Other receivables	1,307.9	1,454.4
Inventories	3,899.4	3,886.0
Prepaid expenses and other	2,806.7	2,530.6
Total current assets	17,115.2	18,452.4
Investments (Note 6)	2,587.2	3,212.6
Goodwill	3,891.8	3,892.0
Other intangibles, net	7,497.7	7,691.9
Deferred tax assets	2,371.9	2,489.3
Property and equipment, net of accumulated depreciation of $10,119.7 (2022) and $9,976.7 (2021)	9,128.2	8,985.1
Other noncurrent assets	4,471.6	4,082.7
Total assets	47,063.6	48,806.0
Current Liabilities
Short-term borrowings and current maturities of long-term debt	2,121.8	1,538.3
Accounts payable	1,659.3	1,670.6
Employee compensation	835.8	958.1
Sales rebates and discounts	7,991.4	6,845.8
Dividends payable	882.2	885.5
Income taxes payable	126.6	126.9
Other current liabilities	2,003.5	3,027.5
Total current liabilities	15,620.6	15,052.7
Other Liabilities
Long-term debt	14,692.0	15,346.4
Accrued retirement benefits (Note 8)	1,888.6	1,954.1
Long-term income taxes payable	3,557.6	3,920.0
Deferred tax liabilities	862.5	1,733.7
Other noncurrent liabilities	1,783.1	1,644.3
Total other liabilities	22,783.8	24,598.5
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity
Common stock	594.1	596.3
Additional paid-in capital	6,746.0	6,833.4
Retained earnings	8,556.0	8,958.5
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 10)	(4,287.7)	(4,343.1)
Cost of common stock in treasury	(50.5)	(52.7)
Total Eli Lilly and Company shareholders' equity	8,544.7	8,979.2
Noncontrolling interests	114.5	175.6
Total equity	8,659.2	9,154.8
Total liabilities and equity	$ 47,063.6	$ 48,806.0